Tetrahedron Letters, Vol.31, No.25, pp 3637-3640, 1990
Printed in Great Britain

0040-4039/90 $3.00 + .00
Pergamon Press plc

ENANTIODIVERGENT TOTAL SYNTHESIS OF NATURALLY OCCURRING *trans*-2-BUTYL-5-PENTYLPYRROLIDINE

Nobuo Machinaga and Chihiro Kibayashi*

Tokyo College of Pharmacy, Horinouchi, Hachioji, Tokyo, 192-03, Japan

Abstract: The enantiodivergent total synthesis of (+)-(2*S*,5*S*)- and (–)-(2*R*,5*R*)-*trans*-2-butyl-5-pentylpyrrolidines was effected from the C_2 symmetric (*S*,*S*)- and (*R*,*R*)-diepoxides, respectively, both prepared from D-mannitol, by a sequence involving stereo-defined ring construction of the unsymmetrical *trans*-2,5-dialkylpyrrolidine via the cyclic sulfate as a key step.

Naturally occurring *trans*-2-butyl-5-pentylpyrrolidine (**1**) has been found as an ant venom alkaloidal component from *Solenopsis punctaticeps*,[1] *Monomorium pharaonis*,[2] and *M. latinode*.[3] Recently, this compound **1** has also been detected in a poison frog *Dendrobates histrionicus* from northwestern Colombia; it has been identified as one of a new class of dendrobates alkaloids and named pyrrolidine 197B.[4] In all these cases of the compound, however, the absolute configuration is unknown. In continuation of our work on the synthesis of dendrobates alkaloids,[5] we have now developed a new chiral approach for this alkaloid. In this paper we report the enantioselective preparation of both enantiomers of **1** based on a stereo-defined method utilizing as a C_2 symmetrical building block, the optically active diepoxide **4**, which is readily available in both enantiomeric forms from D-mannitol as a common chiral synthon. Our results represent the first example of the preparation of optically active **1**.[6]



(+)-**1**



(–)-**1**

The (*S*,*S*)- and (*R*,*R*)-diepoxides **4** are both easily prepared in two and four steps, respectively, by utilizing (*S*,*S*)-1,2,5,6-hexanetetraol (**2**) as a single, common chiral synthon, available from D-mannitol[7] (Scheme 1). Thus, tosylation of the tetraol **2** followed by alkaline treatment provided (*S*,*S*)-**4**, $[\alpha]^{26}_{D}$ –15.8° (*c* 3.80, $CHCl_3$), as an oil in 58% overall yield from **2**. On the other hand, **2** was converted to the dimesylate **5** through

Scheme 1



(a) TsCl (2 equiv), Py; (b) 15% NaOH, THF; (c) *t*-Bu(Me)$_2$SiCl, imidazole, then MsCl, Et_3N, CH_2Cl_2; (d) conc. HCl–MeOH, then 20% KOH, THF.

Scheme 2



(a) $BnO(CH_2)_3MgBr$, cat. CuI, THF, –15 °C; (b) *t*-$Bu(Me)_2SiCl$, imidazole, DMF; (c) H_2, Pd–C, MeOH; (d) $PhCH_2Br$ (1 equiv), NaH, DMF; (e) TsCl, *N,N*-dimethylaminopyridine, CH_2Cl_2; (f) $LiAlH_4$, THF; (g) MeMgBr, cat. Li_2CuCl_4, THF, –78–0 °C; (h) conc. HCl–MeOH, 0 °C; (i) $SOCl_2$, Et_3N, CH_2Cl_2; then $NaIO_4$, cat. $RuCl_3$, $MeCN–H_2O$; (j) LiN_3, DMF, then cat. H_2SO_4, THF; (k) MsCl, Et_3N, CH_2Cl_2.

protection of the primary alcohol function followed by mesylation in 77% yield. Deprotection and alkaline treatment led to the (*R*,*R*)-diepoxide **4**, $[\alpha]^{26}_D$ +15.8° (*c* 2.22, $CHCl_3$), in 51% yield from **5**.

The (*R*,*R*)-diepoxides **4** thus obtained was treated with 2 equiv of 3-benzyloxypropylmagnesium bromide in the presence of a catalytic amount of cuprous ion (CuI, THF, –15 °C) to produce the dibenzyl compound **6** (62%); this was then converted to the diol (*S*,*S*)-**7** (91%) via silylation followed by debenzylation by hydrogenolysis (H_2, Pd–C). Monobenzylation of the diol (*S*,*S*)-**7** with C_2 symmetry was effected by treatment with 1 equiv of benzylbromide and NaH in DMF to give **8** (60%) with unsymmetrical structure, which was then converted to the tosylate **9** (100%) by a standard procedure (Scheme 2). After reduction with $LiAlH_4$, resulting **10** was subjected to debenzylation by hydrogenolysis (75% from **9**) and subsequent tosylation to give (5*S*,8*S*)-**11** (100%), which underwent coupling with methylmagnesium bromide in the presence of a catalyst (Li_2CuCl_4) to yield **12** (76%). When the diol **13**, obtained by deprotection of the disilyl ether **12**, was treated with thionyl chloride and triethylamine, followed by a catalytic amount of RuO_4 according to the Sharpless procedure,[8] the cyclic sulfate (3*S*,6*S*)-**14**, $[\alpha]^{26}_D$ +19.9° (*c* 1.36, $CHCl_3$), was produced in 77% overall yield from **13**. Nucleophilic ring opening of the cyclic sulfate by treatment with LiN_3, followed by hydrolysis of the resulting sulfate, afforded a 1:1 mixture (92% yield) of the two azides **15a** and **15b**, which was, without separation, converted to a mixture of the correponding mesylates **16a** and **16b** in 91% yield. These structural isomers **16a** and **16b** can be both convergently led to the same product by an intramolecular cyclization with inversion of the configurations of the carbons bearing the mesyloxy groups. Thus, the resultant 1:1 mixture of **16a** and **16b**, without separation, underwent hydrogenation over palladium on carbon, exclusively producing (2*R*,5*R*)-*trans*-2-butyl-5-pentylpyrrolidine [(–)-**1**],[9] oil; $[\alpha]^{27}_D$ –5.8° (*c* 0.61, $CHCl_3$),[10] in 91% yield.[11] Synthetic (–)-**1** exhibited the mass spectrum identical with that published for the natural alkaloid from both *S. punctaticeps*[1] and *D. histrionicus*.[4]

For the synthesis of the (+)-enantiomer of **1**, we employed a more convenient short route starting with the (*S*,*S*)-diepoxide **4** (Scheme 3). Thus, (*S*,*S*)-**4** was converted to the C_2 symmetrical diol (*R*,*R*)-**7** in the same

Scheme 3



(a) 3 steps as in Scheme 2; (b) TsCl (2 equiv), *N*,*N*-dimethylaminopyridine, CH_2Cl_2; (c) $LiEt_3BH$ (1 equiv), THF, 0 °C; (d) 4 steps as in Scheme 2; (e) 4 steps as in Scheme 2.

manner as described above for (*S*,*S*)-**7**. After tosylation of (*R*,*R*)-**7**, the resulting ditosylate **17** was treated with 1 equiv of super hydride ($LiEt_3BH$) in THF at 0 °C. In this way, the monotosylate (5*R*,8*R*)-**11** was obtained in 60% yield (90% based on recovered **17**). This product was led to (+)-**1**, $[\alpha]^{27}_D$ +5.8° (*c* 0.79, $CHCl_3$), via the cyclic sulfate (3*R*,6*R*)-**14**, $[\alpha]^{22}_D$ −19.0° (*c* 1.00, $CHCl_3$), by the same procedure as that used for the preparation of (−)-**1** above.

Up to now, a total of seventeen 2,5-dialkylpyrrolidine analogs (including **1**) have been found in the secretions of thief ants and fire ants of the genera *Solenopsis* and *Monomorium*.[13,3] These naturally occurring pyrrolidines reportedly are all of the trans configuration although the absolute configuration of the chiral centers still remains unknown. The enantioselective preparation of the unsymmetrical *trans*-2,5-dialkylpyrrolidine in both enantiomeric forms described in this paper would provide a methodology efficiently applicable to the synthesis of these alkaloids, which are naturally produced only in trace amounts.

References and Notes

1. D. J. Pedder, H. M. Fales, T. Jaouni, M. Blum, J. MacConnell, and R. M. Crewe, *Tetrahedron*, **1976**, *32*, 2275.
2. F. J. Ritter and C. J. Persoons, *Neth. J. Zool.*, **1975**, *25*, 261.
3. T. H. Jones, M. S. Blum, and H. M. Fales, *Tetrahedron*, **1982**, *38*, 1949.
4. J. W. Daly, T. F. Spande, N. Whittaker, R. J. Highet, D. Feigl, N. Nishimori, T. Tokuyama, and C. W. Myers, *J. Nat. Prod.*, **1986**, *49*, 265.
5. (a) H. Iida, Y. Watanabe, and C. Kibayashi, *J. Am. Chem. Soc.*, **1985**, *107*, 5534. (b) N. Yamazaki and C. Kibayashi, *Ibid.*, **1989**, *111*, 1396.
6. For recent synthesis of racemic **1**, see: (a) T. H. Jones, M. S. Blum, and H. M. Fales, *Tetrahedron Lett.*, **1979**, 1031. (b) T. L. MacDonalds, *J. Org. Chem.*, **1980**, *50*, 1229. (c) W. Gessner, K. Takahashi, A. Brossi, M. Kowalski, and M. A. Kaliner, *Helv. Chim. Acta*, **1987**, *70*, 2003.
7. C. C. Deane and T. D. Inch, *J. Chem. Soc., Chem. Commun.*, **1969**, 813.
8. (a) Y. Gao and K. B. Sharpless, *J. Am. Chem. Soc.*, **1988**, *110*, 7538. (b) B. M. Kim and K. B. Sharpless, *Tetrahedron Lett.*, **1989**, *30*, 655.
9. ^1H NMR (400 MHz, $CDCl_3$) δ 0.87 (3 H, t, *J* = 7.0 Hz), 0.89 (3 H, t, *J* = 7.0 Hz), 1.29–2.22 (18 H, m), 3.57–3.64 (2 H, unresolved); ^{13}C NMR (100.6 MHz, $CDCl_3$) δ 13.95, 14.00, 22.44, 22.55, 25.82, 26.33, 28.74, 29.63, 30.42, 30.45, 31.56, 32.39, 32.65, 59.57, 59.63.
10. No rotation data have been reported for the natural product.[1-4]
11. The trans stereochemistry of the product (+)-**1** was verified by the method of Hill and Chans[12] based on analysis of the benzyl methylene signal (δ 3.64 and 3.81, AB q, *J* = 13.9 Hz) in the ^1H NMR spectrum ($CDCl_3$) of the *N*-benzylpyrrolidine **ii** derived from (+)-**1** as follows.



(+)-**1** **I** **II**

12. R. K. Hill and T.-H. Chan, *Tetrahedron*, **1965**, *21*, 2015.
13. For reviews of pyrrolidine alkaloids, see: (a) T. H. Jones and M. S. Blum, in "Alkaloids: Chemical and Biological Perspectives," Ed. S. W. Pelletier, Wiley-Interscience, New York, 1983, Vol. 1, Chapter 2. (b) A. B. Attygalle and E. D. Morgan, *Chem. Soc. Rev.*, **1984**, *13*, 245. (c) G. Massiot and C. Delaude, in "The Alkaloids," Ed. A. Brossi, Academic Press, New York, 1986, Vol. 27, Chapter 3. (d) A. Numata and T. Ibuka, in "The Alkaloids," Ed. A. Brossi, Academic Press, New York, 1987, Vol. 31, Chapter 6.

(Received in Japan 16 April 1990)